Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
NICE recommends these early in treatment for many people with established cardiovascular disease or chronic kidney disease [3] Pioglitazone : An insulin sensitiser, though less commonly used due to side effects including weight gain and fluid retention DPP-4 inhibitors : These enhance incretin activity with a lower side effect burden than GLP-1 agonists but less weight loss benefit Tirzepatide : A newer dual GIP/GLP-1 receptor agonist available for type 2 diabetes (subject to local formulary approval) [3] For patients who cannot tolerate or do not respond adequately to Ozempic, other GLP-1 receptor agonists such as dulaglutide (Trulicity) or liraglutide (Victoza) may be considered
What the Research Says While formal studies on microdosing are limited, early data suggest potential benefits for select populations
This study reveals that increased AR expression in melanoma cells is both required and sufficient to confer resistance to BRAF inhibitors through transcriptional activation mechanisms that can be targeted
Selenium and selenocysteine: roles in cancer, health, and development
